ArticleArchives of toxicology2025
Absolute oral bioavailability, quantitative toxicokinetics and metabolite profiling of alternariol and alternariol monomethyl ether in pigs.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Food to Humans: The Toxicological Effects ofJournal of xenobiotics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The mycotoxins alternariol (AOH) and alternariol monomethyl ether (AME), produced by Alternaria spp., are common contaminants of food and feed and are a potential threat to animal and human health. To date, the most prominent data gaps for their comprehensive risk assessment concern information on their in vivo absorption, distribution, metabolism and excretion (ADME) and toxicokinetic behavior. The aim of this study was to determine the absolute oral bioavailability, quantitative toxicokinetic characteristics and biotransformation of AOH and AME in vivo in pigs, using crossover trials with intravenous and oral administration of a single dose of both mycotoxins at 2 mg/kg b.w. Plasma profiles of the mycotoxins and phase I and II metabolites were studied in the vena jugularis using UPLC-MS/MS and LC-HRMS methods. Furthermore, plasma from the vena portae was analyzed to study presystemic biotransformation. Urine was collected to determine the urinary excretion and metabolite profiles. Results reveal a low absolute oral bioavailability of AOH (15%) and AME (9%), caused by a low absorption and/or extensive first-pass biotransformation in the liver to mainly phase II, and to a lesser extent phase I metabolites. Quantitative toxicokinetic modeling of the IV data showed a high total body clearance for both AOH and AME (12.9 and 16.8 L/(h*kg b.w.), respectively), a high volume of distribution (4.97 and 5.15 L/kg b.w., respectively) and a short elimination half-life of 0.16 and 0.21 h, respectively. These findings may contribute to the risk assessment of AOH and AME and to the development of candidate biomarkers of exposure in biomonitoring studies since pigs are considered a suitable animal model to extrapolate to humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.